Detalhe da pesquisa
1.
Recurrent repeat expansions in human cancer genomes.
Nature
; 613(7942): 96-102, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36517591
2.
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
; 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38635050
3.
Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
BMC Cancer
; 24(1): 482, 2024 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38627648
4.
Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program.
Support Care Cancer
; 32(3): 161, 2024 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38366165
5.
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Clin Chem
; 67(3): 534-542, 2021 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33393992
6.
18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer.
Eur J Nucl Med Mol Imaging
; 46(7): 1518-1523, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-30850872
7.
Alteration of the lipid profile in lymphomas induced by MYC overexpression.
Proc Natl Acad Sci U S A
; 111(29): 10450-5, 2014 Jul 22.
Artigo
Inglês
| MEDLINE | ID: mdl-24994904
8.
Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
J Am Acad Dermatol
; 85(6): 1610-1611, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33301805
9.
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
Blood
; 122(16): 2864-76, 2013 Oct 17.
Artigo
Inglês
| MEDLINE | ID: mdl-23943652
10.
Diverse and abundant phages exploit conjugative plasmids.
Nat Commun
; 15(1): 3197, 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38609370
11.
Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical Trial.
JAMA Oncol
; 2024 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38780960
12.
Proteomic Discovery of RNA-Protein Molecular Clamps Using a Thermal Shift Assay with ATP and RNA (TSAR).
bioRxiv
; 2024 Apr 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38659867
13.
THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY.
medRxiv
; 2024 Jan 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38343840
14.
Automated Image Analysis for Characterization of Circulating Tumor Cells and Clusters Sorted by Magnetic Levitation.
Adv Biol (Weinh)
; 7(10): e2300109, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37462226
15.
Diverse and abundant phages exploit conjugative plasmids.
bioRxiv
; 2023 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36993299
16.
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
JCO Oncol Pract
; 19(2): e176-e184, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36395436
17.
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds.
Proc Natl Acad Sci U S A
; 106(11): 4390-5, 2009 Mar 17.
Artigo
Inglês
| MEDLINE | ID: mdl-19251665
18.
Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS).
Urol Oncol
; 40(1): 12.e23-12.e30, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34580027
19.
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Clin Cancer Res
; 28(15): 3248-3255, 2022 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35576438
20.
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Clin Cancer Res
; 28(8): 1540-1548, 2022 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35140121